Gubra

Dagens aktienyheder 05/02-2026: Gubra, Danske bank, Ascelia Pharma

I dagens Morgenbørs ser vi ind i US futures der ligger marginalt i minus, mens EU peger op fra morgenstunden. Afventende stemning op til at højesteret i USA kommer med afgørelse om Trumps tariffer.

Dagens aktienyheder 09/01-2026: Gubra og GrønlandsBANKEN

Amylyx Pharmaceuticals has selected AMX0318, a long-acting drug discovered with Gubra, as a development candidate, triggering a USD 4m milestone and carrying >USD 50m in potential milestones plus royalties. While modest versus Gubra’s AbbVie partnership and UCN2, the progression further validates the streaMLine platform and its long-term optionality.

I dagens Morgenbørs ser vi ind positive europæiske futures trukket op af en stærkt luk i US og ignorerende weekendens geopolitik. Herhjemme er der fokus på blandt andet Novo Gubra, ISS og Grønland.

Dagens aktienyheder 05/01-2026 med Gubra

Gubra has entered into an exclusive collaboration and license agreement with Camurus to develop a long-acting treatment for hypoparathyroidism, combining Gubra’s parathyroid hormone (PTH) analogue (discovered via its AI-enabled streaMLine platform) with Camurus’ FluidCrystal® sustained-release technology. The aim is to reduce injection frequency and improve disease control versus current once-daily PTH therapies, addressing a clear unmet need in this rare endocrine disorder. 

I dagens Morgenbørs ser vi ind i endnu en positiv dag på de europæiske futures og positive globale markeder efter FED møde. Herhjemme fokus på blandt andet FLS, Bavarian og fedme aktier.

Dagens aktienyheder med Gubra og Impero - Compliance. Simplified.

Gubra announced this morning that its partner, Boehringer Ingelheim, is advancing BI 3034701, a next-generation triple-agonist peptide for the treatment of obesity, into mid-stage clinical development following completion of the Phase I study. No data have been released, but the decision to progress the candidate follows a randomized, placebo-controlled Phase I trial in healthy volunteers and individuals with overweight or obesity, in which BI 3034701 demonstrated a favourable safety and tolerability profile together with promising early weight-loss effects.

I dagens Morgenbørs ser vi ind i små fald i de Europæiske futures afventede på FED. Herhjemme fokus på blandt andet Gubra, Lundbeck og Genmab.

Dagens aktienyheder med Gubra og Hafnia

Dagens aktienyheder med Vestjysk Bank, BioPorto A/S, ALK og Gubra